These are data to week 26 on the monoclonal antibody and antineoplastic agent; data out to week 52 of the MINT trial will be ...

The pivotal Phase III study in myasthenia gravis met its primary endpoint with meaningful improvements in MG-ADL across both higher and lower dose arms.

Immunovant (IMVT) reported topline results from its Phase 3 study of batoclimab in MG and initial results from Period 1 of its Phase 2b study ...

Pivotal study in MG met primary endpoint of change from baseline in MG-ADL in AChR+ population at 12 weeks, with a 5.6 point improvement in the higher dose arm (with ...

Pivotal study in MG met primary endpoint of change from baseline in MG-ADL in AChR+ population at 12 weeks, with a 5.6 point improvement in the higher dose arm (with 74% mean IgG reduction) and a 4.7 ...

At week 52, results showed AChR+ patients treated with inebilizumab continued to improve based on the change from baseline in MG-ADL score vs placebo. Treatment with inebilizumab was associated with ...

Data from the study showed that treatment with Uplizna ‘demonstrated durable and sustained efficacy’ in AChR-positive (AChR+) gMG patients over 52 weeks. These findings were assessed using the ...

The trial focused on patients with acetylcholine receptor autoantibody-positive (AChR+) gMG, showing continued improvement in daily activities compared to placebo over 52 weeks. The MINT trial, a ...